73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Lyell Immunopharma Inc
Closed
23.36 -0.13
Overview
Share price change
24h
Min
22.77
Max
24.2
Income | 3.8M -39M |
|---|---|
Sales | 7K 15K |
EPS | -2.13 |
Profit margin | -258,973.333 |
Employees | 300 |
EBITDA | 6.3M -36M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +19.9% upside |
Next Earnings | 9 Mar 2026 |
|---|
Market Cap | 165M 505M |
|---|---|
Previous open | 23.49 |
Previous close | 23.36 |
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Lyell Immunopharma Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Lyell Immunopharma Inc Forecast
Price Target
By TipRanks
19.9% upside
12 Months Forecast
Average 28.5 USD 19.9%
High 45 USD
Low 12 USD
Based on 2 Wall Street analysts offering 12 month price targets forLyell Immunopharma Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
Live chat